| Literature DB >> 21698235 |
Spiridoula Athanasiadou1, Leigh A Jones, Stewart T G Burgess, Ilias Kyriazakis, Alan D Pemberton, Jos G M Houdijk, John F Huntley.
Abstract
BACKGROUND: Gastrointestinal nematode infection is a major challenge to the health and welfare of mammals. Although mammals eventually acquire immunity to nematodes, this breaks down around parturition, which renders periparturient mammals susceptible to re-infection and an infection source for their offspring. Nutrient supplementation reduces the extent of periparturient parasitism, but the underlying mechanisms remain unclear. Here, we use a genome wide approach to assess the effects of protein supplementation on gene expression in the small intestine of periparturient rats following nematode re-infection. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2011 PMID: 21698235 PMCID: PMC3116830 DOI: 10.1371/journal.pone.0020771
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Genes significantly differentially regulated by secondary challenge with N.brasiliensis in lactating rats (P<0.05, FC>2*, MTC 0.05).
| Gene symbol | Gene description | Fold Change | Location | Type(s) |
|
| Dual oxidase maturation factor 2 | 11.8 | Cytoplasm | other |
|
| Dual oxidase 2 | 8.3 | unknown | enzyme |
|
| Mast cell protease 4 | 7.7 | Extracellular Space | peptidase |
|
| Phospholipase A2, group IVC (cytosolic, calcium-independent) | 4.3 | Cytoplasm | enzyme |
|
| Resistin like beta | 3.9 | Extracellular Space | other |
|
| CD55 molecule | 3.7 | Plasma Membrane | other |
|
| Tryptase beta 2 | 3.7 | Extracellular Space | peptidase |
|
| Mast cell protease 8 | 3.5 | Extracellular Space | peptidase |
|
| Tryptase gamma 1 | 3.2 | Extracellular Space | peptidase |
|
| Interleukin 1 receptor-like 1 | 3.1 | Plasma Membrane | transmembrane receptor |
|
| Gasdermin C | 3.0 | Cytoplasm | other |
|
| Periostin, osteoblast specific factor | 3.0 | Extracellular Space | other |
|
| Mast cell protease 1 | 2.9 | Extracellular Space | peptidase |
|
| Carboxypeptidase A3 (mast cell) | 2.7 | Extracellular Space | peptidase |
|
| Mast cell protease 4 | 2.6 | Extracellular Space | peptidase |
|
| Glutathione peroxidase 2 (gastrointestinal) | 2.6 | Cytoplasm | enzyme |
|
| Calponin 1, basic, smooth muscle | 2.6 | Cytoplasm | other |
|
| Serglycin | 2.5 | Extracellular Space | other |
|
| Desmin | 2.5 | Cytoplasm | other |
|
| Serine peptidase inhibitor, Kazal type 4 | 2.5 | Extracellular Space | other |
|
| Regulator of G-protein signaling 13 | 2.5 | Nucleus | other |
|
| Apolipoprotein L, 3 | 2.4 | Cytoplasm | transporter |
|
| Actin, gamma 2, smooth muscle, enteric | 2.4 | Cytoplasm | other |
|
| Intelectin 1 (galactofuranose binding) | 2.3 | Plasma Membrane | other |
|
| Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) | 2.2 | Plasma Membrane | other |
|
| SH2 domain containing 6 | 2.2 | unknown | other |
|
| Lectin, galactoside-binding, soluble, 1 | 2.2 | Extracellular Space | other |
|
| Chymase 1, mast cell | 2.1 | Extracellular Space | peptidase |
|
| Matrix metallopeptidase 10 (stromelysin 2) | 2.0 | Extracellular Space | peptidase |
|
| Natural killer cell group 7 sequence | 2.0 | Plasma Membrane | other |
|
| Deoxyribonuclease I | −2.0 | Extracellular Space | enzyme |
|
| Glucose-6-phosphatase, catalytic subunit | −3.2 | Cytoplasm | phosphatase |
*For extended list of genes (FC>1.5) see Table S1.
Top biological processes significantly affected by secondary challenge with Nippostrongylus brasiliensis in lactating rats.
| Category | Enrichment (P-value) | Molecule counts |
| Cellular Movement | 3.94E-11-5E-03 | 33 |
| Respiratory Disease | 3.96E-11-5E-03 | 22 |
| Haematological System Development and Function | 2.54E-10-5E-03 | 25 |
| Immune Cell Trafficking | 2.54E-10-5E-03 | 23 |
| Inflammatory Disease | 1.26E-09-5E-03 | 31 |
| Inflammatory Response | 1.34E-09-5E-03 | 31 |
| Genetic Disorder | 2.83E-09-4.87E-03 | 56 |
| Cell-To-Cell Signalling and Interaction | 8.43E-09-5E-03 | 24 |
| Tissue Development | 6.69E-08-5E-03 | 20 |
| Lipid Metabolism | 1.33E-07-5E-03 | 17 |
| Molecular Transport | 1.33E-07-5E-03 | 27 |
| Small Molecule Biochemistry | 1.33E-07-5E-03 | 20 |
| Cell Death | 2.29E-07-5E-03 | 31 |
| DNA Replication, Recombination, and Repair | 2.52E-07-5E-03 | 13 |
| Cardiovascular Disease | 6.23E-07-5E-03 | 32 |
| Organismal Functions | 7.85E-07-7.37E-05 | 8 |
| Tissue Morphology | 8.94E-07-1.04E-03 | 13 |
| Cell Morphology | 1.65E-06-5E-03 | 16 |
| Cellular Development | 1.65E-06-5E-03 | 25 |
| Cardiovascular System Development and Function | 2.53E-06-5E-03 | 18 |
| Organ Morphology | 2.53E-06-1.47E-04 | 7 |
| Cell-mediated Immune Response | 2.84E-06-5E-03 | 8 |
| Connective Tissue Disorders | 3.05E-06-4.56E-03 | 20 |
| Skeletal and Muscular Disorders | 3.05E-06-4.56E-03 | 31 |
| Skeletal and Muscular System Development and Function | 3.28E-06-5E-03 | 16 |
| Cellular Growth and Proliferation | 1.02E-05-3.99E-03 | 30 |
| Embryonic Development | 1.07E-05-5E-03 | 8 |
| Protein Degradation | 1.11E-05-1.11E-05 | 8 |
| Protein Synthesis | 1.11E-05-1.98E-03 | 10 |
| Cell Signaling | 1.14E-05-1.2E-03 | 15 |
*The P value reported here is a range between the most and least significant result, for the various molecules represented in each biological process.
Canonical pathways significantly affected by secondary challenge with Nippostrongylus brasiliensis in lactating rats.
| Canonical pathways | −log(p-value) | Ratio | Molecules |
| Eicosanoid Signaling | 4.78E00 | 6.02E-02 | 5 |
| ILK Signaling | 4.53E00 | 3.76E-02 | 7 |
| Leukocyte Extravasation Signaling | 3.49E00 | 3.09E-02 | 6 |
| IL-17 Signaling | 3.34E00 | 5.41E-02 | 4 |
| Caveolar-mediated Endocytosis Signaling | 3.29E00 | 4.82E-02 | 6 |
| Actin Cytoskeleton Signaling | 3.2E00 | 2.58E-02 | 5 |
| Arachidonic Acid Metabolism | 3.12E00 | 2.21E-02 | 4 |
| TR/RXR Activation | 3.05E00 | 4.12E-02 | 4 |
| Virus Entry via Endocytic Pathways | 3.05E00 | 4.17E-02 | 4 |
| Atherosclerosis Signaling | 2.82E00 | 3.57E-02 | 4 |
| Glioma Invasiveness Signaling | 2.61E00 | 5.26E-02 | 3 |
| Agrin Interactions at Neuromuscular Junction | 2.32E00 | 4.35E-02 | 3 |
| PAK Signaling | 2.04E00 | 2.94E-02 | 3 |
| FXR/RXR Activation | 2.01E00 | 2.91E-02 | 3 |
| NRF2-mediated Oxidative Stress Response | 1.98E00 | 2.19E-02 | 4 |
| Oncostatin M Signaling | 1.9E00 | 5.71E-02 | 2 |
| Coagulation System | 1.83E00 | 5.41E-02 | 2 |
| MIF Regulation of Innate Immunity | 1.83E00 | 4.35E-02 | 2 |
| Rac Signaling | 1.83E00 | 2.5E-02 | 3 |
| RhoA Signaling | 1.78E00 | 2.73E-02 | 3 |
| CCR3 Signaling in Eosinophils | 1.77E00 | 2.5E-02 | 3 |
| Cdc42 Signaling | 1.77E00 | 2.44E-02 | 3 |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | 1.58E00 | 2.24E-02 | 3 |
| Phospholipase C Signaling | 1.57E00 | 1.58E-02 | 4 |
| Galactose Metabolism | 1.51E00 | 1.74E-02 | 2 |
| TREM1 Signaling | 1.48E00 | 2.9E-02 | 2 |
Figure 1Graphical representation of network 1 as affected by secondary parasite challenge.
Network score = 38. Individual nodes represent protein functions with relationships represented by edges. Nodes are colored by change in gene expression, red indicating up-regulation in infected rats, green indicating down-regulation in infected rats and white indicating that the gene/factor was not differentially expressed but showed a defined relationship to the other genes in the network. Arrows indicate directional relationships between genes.
Genes significantly differentially regulated by protein supplementation in lactating rats (P<0.05, FC>1.5, MTC 0.05).
| Gene symbol | Gene description | Fold Change | Location | Type(s) |
|
| Alcohol dehydrogenase 1C (class I), gamma polypeptide | 3.6 | Cytoplasm | enzyme |
|
| Solute carrier family 11, member 2 | 2.0 | Plasma Membrane | transporter |
|
| NADH dehydrogenase, subunit 5 (complex I) | 1.9 | Cytoplasm | enzyme |
|
| Ribosomal protein S19 | 1.8 | Cytoplasm | other |
|
| Ribosomal protein S15a | 1.8 | Cytoplasm | other |
|
| Ferritin, light polypeptide | 1.7 | Cytoplasm | other |
|
| ATP synthase, H+ transporting, subunit E | 1.7 | Cytoplasm | transporter |
|
| Interleukin 1 receptor, type II | 1.7 | Plasma Membrane | transmembrane receptor |
|
| V-set and immunoglobulin domain containing 4 | 1.7 | Plasma Membrane | other |
|
| Histone cluster 2, H2ab | 1.7 | Nucleus | other |
|
| Predicted gene 6744 | 1.7 | unknown | other |
|
| Ribosomal protein L41 | 1.6 | Cytoplasm | other |
|
| Cytochrome b reductase 1 | 1.6 | Cytoplasm | enzyme |
|
| Ribosomal protein S12 | 1.6 | Cytoplasm | other |
|
| Ribosomal protein L41 | 1.6 | Cytoplasm | other |
|
| Histone cluster 1, H2bk | 1.5 | Nucleus | other |
|
| Ribosomal protein S9 | 1.5 | Cytoplasm | other |
|
| Histone cluster 2, H3c | 1.5 | Nucleus | other |
|
| Ribosomal protein L22 | 1.5 | Nucleus | other |
|
| Similar to eukaryotic translation elongation factor 1 alpha 1 | −1.5 | unknown | other |
|
| Family with sequence similarity 190, member B | −1.5 | unknown | other |
|
| Guanylate cyclase activator 2A (guanylin) | −1.5 | Extracellular Space | other |
|
| Phosphatidic acid phosphatase type 2A | −1.5 | Plasma Membrane | phosphatase |
|
| Solute carrier family 20 (phosphate transporter), member 1 | −1.6 | Plasma Membrane | transporter |
|
| Peroxisome proliferator-activated receptor gamma, coactivator 1a | −1.6 | Nucleus | transcription regulator |
|
| Vanin 1 | −1.6 | Plasma Membrane | enzyme |
|
| CD3g molecule, gamma (CD3-TCR complex) | −1.9 | Plasma Membrane | transmembrane receptor |
| N/A | 5S ribosomal RNA | 6.1 | Cytoplasm | non-coding RNA |
| N/A | novel pseudogene | 1.7 | Cytoplasm | non-coding RNA |
| N/A | U6 snRNA spliceosomal RNA | 1.6 | Nucleus | non-coding RNA |
| N/A | Small nucleolar RNA Z195/SNORD33 | 1.5 | Nucleus | non-coding RNA |
| N/A | Y RNA | 1.5 | Nucleus | non-coding RNA |
| N/A | Mt tRNA | 1.5 | Cytoplasm | non-coding RNA |
| N/A | signal recognition particle (SRP) RNA | 1.5 | Cytoplasm | non-coding RNA |
Top biological processes significantly affected by protein supplementation in lactating rats.
| Category | Enrichment(P value) | Molecule counts |
| Protein Synthesis | 1.13E-04-1.13E-04 | 5 |
| Carbohydrate Metabolism | 1.51E-03-4.21E-02 | 4 |
| Cellular Function and Maintenance | 1.51E-03-3.56E-02 | 3 |
| Digestive System Development and Function | 1.51E-03-1.51E-03 | 1 |
| Genetic Disorder | 1.51E-03-9E-03 | 3 |
| Lipid Metabolism | 1.51E-03-3.85E-02 | 4 |
| Neurological Disease | 1.51E-03-3.85E-02 | 2 |
| Ophthalmic Disease | 1.51E-03-1.51E-03 | 1 |
| Skeletal and Muscular System Development and Function | 1.51E-03-2.38E-02 | 2 |
| Small Molecule Biochemistry | 1.51E-03-4.28E-02 | 7 |
| Tissue Morphology | 1.51E-03-2.84E-02 | 5 |
| Hematological Disease | 1.63E-03-4.71E-02 | 6 |
| Behavior | 3.01E-03-1.2E-02 | 1 |
| Cellular Development | 3.01E-03-4.57E-02 | 5 |
| Cellular Growth and Proliferation | 3.01E-03-3.17E-02 | 4 |
| Drug Metabolism | 3.01E-03-2.68E-02 | 1 |
| Gene Expression | 3.01E-03-2.83E-02 | 1 |
| Hematological System Development and Function | 3.01E-03-4.57E-02 | 4 |
| Hematopoiesis | 3.01E-03-4.57E-02 | 2 |
| Hepatic System Development and Function | 3.01E-03-1.5E-02 | 1 |
| Molecular Transport | 3.01E-03-2.83E-02 | 5 |
| Organismal Functions | 3.01E-03-2.38E-02 | 1 |
| Organismal Injury and Abnormalities | 3.01E-03-3.85E-02 | 3 |
| Vitamin and Mineral Metabolism | 3.01E-03-3.41E-02 | 4 |
| Cancer | 4.51E-03-4.82E-02 | 7 |
| Cell Death | 4.51E-03-3.56E-02 | 2 |
| Cell Morphology | 4.51E-03-4.14E-02 | 2 |
| Cellular Assembly and Organization | 4.51E-03-3.99E-02 | 1 |
| Nervous System Development and Function | 4.51E-03-3.7E-02 | 4 |
| Reproductive System Disease | 4.51E-03-4.82E-02 | 2 |
*The P value reported here is a range between the most and least significant result, for the various molecules represented in each biological process.
Canonical pathways significantly affected by protein supplementation in lactating rats.
| Ingenuity Canonical Pathways | −log(p-value) | Ratio | Molecule counts |
| Sphingolipid Metabolism | 2.14E00 | 1.79E-02 | 2 |
| PPAR Signaling | 2.13E00 | 2.04E-02 | 2 |
| p38 MAPK Signaling | 2.03E00 | 2.06E-02 | 2 |
| Glycerolipid Metabolism | 1.97E00 | 1.28E-02 | 2 |
| Estrogen Receptor Signaling | 1.93E00 | 1.68E-02 | 2 |
| Lysine Biosynthesis | 1.75E00 | 1.52E-02 | 1 |
| Oxidative Phosphorylation | 1.67E00 | 1.2E-02 | 2 |
| PPARα/RXRα Activation | 1.6E00 | 1.1E-02 | 2 |
| Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells | 1.4E00 | 3.12E-02 | 1 |
Figure 2Graphical representation of merged networks 1 and 2 as affected by protein supplementation.
Scores of individual networks: 33 and 19. Individual nodes represent protein functions with relationships represented by edges. Nodes are colored by change in gene expression, red indicating up-regulation in HP rats, green indicating down-regulation in HP rats and white indicating that the gene/factor was not differentially expressed but showed a defined relationship to the other genes in the network. Arrows indicate directional relationships between genes.
Top biological processes significantly affected by the interaction between protein supplementation and secondary challenge.
| Category | Enrichment(P value) | Molecule counts |
| Carbohydrate Metabolism | 8E-04-4.87E-02 | 7 |
| Cell-To-Cell Signaling and Interaction | 1.1E-03-3.4E-02 | 9 |
| Cellular Function and Maintenance | 1.1E-03-3.77E-02 | 3 |
| Inflammatory Response | 1.1E-03-1.1E-03 | 2 |
| Amino Acid Metabolism | 3.83E-03-3.03E-02 | 1 |
| Auditory and Vestibular System Development and Function | 3.83E-03-3.83E-03 | 1 |
| Cardiovascular System Development and Function | 3.83E-03-4.87E-02 | 5 |
| Cell Cycle | 3.83E-03-3.77E-02 | 3 |
| Cell Death | 3.83E-03-1.52E-02 | 5 |
| Cellular Assembly and Organization | 3.83E-03-3.77E-02 | 4 |
| Cellular Development | 3.83E-03-3.77E-02 | 7 |
| Cellular Growth and Proliferation | 3.83E-03-4.87E-02 | 14 |
| DNA Replication, Recombination, and Repair | 3.83E-03-2.28E-02 | 2 |
| Developmental Disorder | 3.83E-03-4.87E-02 | 4 |
| Embryonic Development | 3.83E-03-4.87E-02 | 7 |
| Gene Expression | 3.83E-03-2.65E-02 | 12 |
| Genetic Disorder | 3.83E-03-4.87E-02 | 11 |
| Hematological Disease | 3.83E-03-3.4E-02 | 2 |
| Lipid Metabolism | 3.83E-03-4.14E-02 | 6 |
| Molecular Transport | 3.83E-03-4.9E-02 | 10 |
| Nervous System Development and Function | 3.83E-03-4.14E-02 | 3 |
| Neurological Disease | 3.83E-03-4.87E-02 | 8 |
| Ophthalmic Disease | 3.83E-03-3.4E-02 | 2 |
| Organ Development | 3.83E-03-4.51E-02 | 10 |
| Organ Morphology | 3.83E-03-3.4E-02 | 4 |
| Psychological Disorders | 3.83E-03-4.87E-02 | 2 |
| Reproductive System Development and Function | 3.83E-03-4.87E-02 | 5 |
| Reproductive System Disease | 3.83E-03-4.87E-02 | 4 |
| Skeletal and Muscular System Development and Function | 3.83E-03-4.14E-02 | 4 |
| Small Molecule Biochemistry | 3.83E-03-4.51E-02 | 10 |
*The P value reported here is a range between the most and least significant result, for the various molecules represented in each biological process.
Pathways significantly affected by the interaction between protein supplementation and secondary challenge.
| Ingenuity Canonical Pathways | −log(p-value) | Ratio | Molecule counts |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 2.01E00 | 4.65E-02 | 2 |
| TGF-β Signaling | 1.45E00 | 2.41E-02 | 2 |
| Protein Ubiquitination Pathway | 1.45E00 | 1.49E-02 | 3 |
Figure 3Confirmatory q RT PCR analysis of selected genes.
Bars demonstrate fold change difference in mRNA of the genes shown in the x axes as a consequence of (a) secondary parasite challenge or (b) HP supplementation in comparison to non-infected or LP fed rats respectively.
Primer sequence, annealing temperature (AT°C) and PCR product length for genes amplified using qPCR.
| Gene name | Forward Primer | Reverse Primer | AT°C | PCR product (bp) |
|
|
|
| 60 | 176 |
|
|
|
| 61.5 | 213 |
|
|
|
| 60 | 352 |
|
|
|
| 60 | 201 |
|
|
|
| 59.5 | 149 |
|
|
|
| 59.5 | 194 |
|
|
|
| 59.5 | 202 |
|
|
|
| 61.5 | 246 |
|
|
|
| 61.5 | 194 |
|
|
|
| 61.5 | 200 |
|
|
|
| 61.5 | 211 |
|
|
|
| 61.5 | 175 |